Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

4D Molecular Therapeutics Inc (FDMT)

4D Molecular Therapeutics Inc (FDMT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 744,523
  • Shares Outstanding, K 51,703
  • Annual Sales, $ 20,720 K
  • Annual Income, $ -100,840 K
  • 60-Month Beta 2.83
  • Price/Sales 37.77
  • Price/Cash Flow N/A
  • Price/Book 1.29
Trade FDMT with:

Options Overview Details

View History
  • Implied Volatility 99.57% ( +12.06%)
  • Historical Volatility 141.08%
  • IV Percentile 82%
  • IV Rank 42.59%
  • IV High 196.67% on 01/26/24
  • IV Low 27.53% on 05/08/24
  • Put/Call Vol Ratio 1.36
  • Today's Volume 700
  • Volume Avg (30-Day) 837
  • Put/Call OI Ratio 1.38
  • Today's Open Interest 9,057
  • Open Int (30-Day) 7,391

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/24
See More
  • Average Estimate -0.72
  • Number of Estimates 4
  • High Estimate -0.67
  • Low Estimate -0.77
  • Prior Year -0.77
  • Growth Rate Est. (year over year) +6.49%

Price Performance

See More
Period Period Low Period High Performance
1-Month
14.15 +1.77%
on 07/19/24
28.93 -50.22%
on 07/17/24
-8.38 (-36.79%)
since 06/18/24
3-Month
14.15 +1.77%
on 07/19/24
28.93 -50.22%
on 07/17/24
-10.85 (-42.97%)
since 04/19/24
52-Week
9.44 +52.54%
on 10/17/23
36.25 -60.28%
on 03/27/24
-3.60 (-20.00%)
since 07/19/23

Most Recent Stories

More News
Markets Today: Stocks Slip on Hawkish Fed Comments

Morning Markets March E-Mini S&P 500 futures (ESH24 ) are down -0.30%, and March Nasdaq 100 E-Mini futures (NQH24 ) are down -0.19%. Stock index futures this morning are mildly lower as higher bond yields...

ESU24 : 5,576.75 (+0.41%)
NQU24 : 19,846.25 (+0.68%)
BA : 179.67 (-0.31%)
APD : 262.91 (-1.38%)
ZS : 188.54 (-0.96%)
MAT : 16.23 (-1.87%)
CYTK : 56.41 (+0.89%)
GWW : 945.83 (-1.20%)
CAT : 347.63 (-2.36%)
EL : 99.18 (+2.35%)
FDMT : 14.40 (-4.89%)
CTLT : 57.91 (-0.14%)
Stocks Set to Open Lower as Investors Weigh Powell’s Remarks, Earnings and Fed Speak in Focus

March S&P 500 E-Mini futures (ESH24) are down -0.24%, and March Nasdaq 100 E-Mini futures (NQH24) are down -0.12% this morning as U.S. Treasury yields climbed on relatively hawkish comments from Federal...

ESH24 : 5,101.67s (-1.01%)
NQH24 : 17,854.75s (-0.94%)
META : 476.79 (+0.20%)
EW : 86.50 (+0.80%)
AMZN : 183.13 (-0.34%)
CHTR : 320.31 (-0.41%)
MCD : 257.28 (-0.86%)
CAT : 347.63 (-2.36%)
LLY : 857.47 (+1.01%)
F : 13.98 (-3.92%)
AMGN : 331.29 (+0.10%)
DIS : 95.74 (-1.08%)
Astellas and 4D Molecular Therapeutics (4DMT) Enter into License Agreement to Use 4DMT's Proprietary Intravitreal R100 Vector for Rare Ophthalmic Targets

/PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503) (President and CEO: Naoki Okamura, "Astellas") and 4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) (CEO: David...

FDMT : 14.40 (-4.89%)
Markets Today: Stocks Higher as Bond Yields Fall on Jobless Claims Surge

Morning Markets June E-Mini S&P 500 futures (ESM2 3) this morning are up +0.03%, and June Nasdaq 100 E-Mini futures (NQM2 3) are up +0.16%. U.S. stock index futures this morning recovered from overnight...

ESU24 : 5,576.75 (+0.41%)
NQU24 : 19,846.25 (+0.68%)
SMTC : 31.66 (-2.46%)
ADBE : 551.00 (-1.05%)
ALV : 97.66 (-10.06%)
IGT : 20.62 (-1.10%)
REVG : 24.58 (+2.85%)
TCOM : 45.36 (+0.07%)
FDMT : 14.40 (-4.89%)
SIG : 84.29 (-1.90%)
OXM : 98.55 (-2.45%)
SMAR : 48.29 (+1.00%)
Stocks Little Changed Before the Open as Investors Weigh Interest Rate Outlook

June S&P 500 futures (ESM23) are up +0.05%, and June Nasdaq 100 E-Mini futures (NQM23) are up +0.15% this morning after three major U.S. benchmark indices finished the regular session mixed as an unexpected...

ESM23 : 4,453.35s (+0.61%)
NQM23 : 15,316.61s (+0.85%)
CPB : 46.40 (-3.15%)
MCHP : 88.77 (-3.00%)
NXPI : 269.29 (-3.57%)
WBD : 8.67 (+1.76%)
WIZZ.LN : 2,061.343 (-8.63%)
GME : 24.97 (-3.52%)
HCP : 33.48 (-0.03%)
EXPI : 13.93 (-0.14%)
CURV : 7.95 (+7.00%)
FDMT : 14.40 (-4.89%)
2 Biotech Stocks That Can Rocket Higher in 2023, According to Wall Street

Recent analyst upgrades suggest these stocks can triple your money or better.

ARDX : 5.51 (+0.36%)
FDMT : 14.40 (-4.89%)
4D Molecular Therapeutics to Participate in Upcoming June Investor Conferences

EMERYVILLE, Calif., June 02, 2022 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics, Inc. (Nasdaq: FDMT), a clinical-stage biotherapeutics company harnessing...

FDMT : 14.40 (-4.89%)
4D Molecular Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Updates

EMERYVILLE, Calif., May 12, 2022 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics, Inc. (Nasdaq: FDMT), a clinical-stage biotherapeutics company harnessing...

FDMT : 14.40 (-4.89%)
4D Molecular Therapeutics to Participate in the BofA Securities 2022 Healthcare Conference

EMERYVILLE, Calif., May 05, 2022 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics, Inc. (Nasdaq: FDMT), a a clinical-stage biotherapeutics company...

FDMT : 14.40 (-4.89%)
4D Molecular Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial of 4D-710, an A101 AAV Vector-based, Aerosol-delivered Genetic Medicine for the Treatment of Cystic Fibrosis

EMERYVILLE, Calif., April 04, 2022 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics, Inc. (4DMT) (Nasdaq: FDMT), a clinical-stage biotherapeutics company...

FDMT : 14.40 (-4.89%)

Business Summary

4D Molecular Therapeutics Inc. is a clinical-stage gene therapy company which develops product candidates using its targeted and evolved adeno-associated viruses vectors. It offers a portfolio of gene therapy product candidates focusing on the ophthalmology, cardiology and pulmonology therapeutic areas....

See More

Key Turning Points

3rd Resistance Point 16.13
2nd Resistance Point 15.69
1st Resistance Point 15.04
Last Price 14.40
1st Support Level 13.95
2nd Support Level 13.51
3rd Support Level 12.86

See More

52-Week High 36.25
Fibonacci 61.8% 26.01
Fibonacci 50% 22.84
Fibonacci 38.2% 19.68
Last Price 14.40
52-Week Low 9.44

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar